Georgios Kalampounias

Mr. Georgios Kalampounias

Department of Biology, University of Patras, Pátrai, Greece
orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 August 2025 in Cells
Verified
Journal Article
Open access
PDF file
Georgios KalampouniasGeorgios Kalampounias
Georgios Kalampounias
TATheodosia Androutsopoulou
Theodosia Androutsopoulou
Panagiotis KatsorisPanagiotis Katsoris
Panagiotis Katsoris
ELK1 is a Transcription factor (TF) belonging to the ETS-domain TF family, mainly activated via RAS-RAF-MEK-ERK signaling. As a nethermost pathway molecule, ELK1 binds to Serum-response elements (SREs) and directly regulates the transcription of Immediate early genes (IEGs) including FOS and EGR1. Due to ELK1’s influence on key cellular processes such as proliferation, migration, apoptosis evasion, and Epithelial-to-mesenchymal transition (EMT), its role as a key contributor to tumorigenesis is emerging. In recent years, elevated expression and/or activation of ELK1 has been reported in various malignancies, including lung, breast, prostate, colorectal, blood, gastric, liver, cervical, thyroid and ovarian cancer. ELK1 acts primarily through direct DNA binding but also through interaction with other oncogenes, noncoding RNA molecules, TFs, and upstream kinases (other than ERK1/2), thus participating in diverse axes of transcriptional regulation. Its crucial role in IEG expression has been particularly implicated in cancer progression, metastasis, and drug resistance. Owing to its role in multiple cellular functions and its subsequent oncogenic potential, further elucidation of intracellular ELK1 interactions is of paramount importance. This review aims to summarize current evidence on ELK1’s involvement in solid tumors, dissect reported mechanistic roles, and highlight recent insights that could fuel future ventures of high translational interest.

4 February 2024 in Journal of Fungi
Verified
Journal Article
Open access
PDF file
Georgios KalampouniasGeorgios Kalampounias
Georgios Kalampounias
CGChrysavgi Gardeli
Chrysavgi Gardeli
SASPYRIDON ALEXIS
SPYRIDON ALEXIS
EAElena Anagnostopoulou
Elena Anagnostopoulou
TATheodosia Androutsopoulou
Theodosia Androutsopoulou
Panagiotis KatsorisPanagiotis Katsoris
Panagiotis Katsoris
Cunninghamella elegans NRRL-1393 is an oleaginous fungus able to synthesize and accumulate unsaturated fatty acids, amongst which the bioactive gamma-linolenic acid (GLA) has potential anti-cancer activities. C. elegans was cultured in shake-flask nitrogen-limited media with either glycerol or glucose (both at ≈60 g/L) employed as the sole substrate. The assimilation rate of both substrates was similar, as the total biomass production reached 13.0–13.5 g/L, c. 350 h after inoculation (for both instances, c. 27–29 g/L of substrate were consumed). Lipid production was slightly higher on glycerol-based media, compared to the growth on glucose (≈8.4 g/L vs. ≈7.0 g/L). Lipids from C. elegans grown on glycerol, containing c. 9.5% w/w of GLA, were transformed into fatty acid lithium salts (FALS), and their effects were assessed on both human normal and cancerous cell lines. The FALS exhibited cytotoxic effects within a 48 h interval with an IC50 of about 60 μg/mL. Additionally, a suppression of migration was shown, as a significant elevation of oxidative stress levels, and the induction of cell death. Elementary differences between normal and cancer cells were not shown, indicating a generic mode of action; however, oxidative stress level augmentation may increase susceptibility to anticancer drugs, improving chemotherapy effectiveness.

27 February 2024 in PLOS ONE
Verified
Journal Article
Open access
PDF file
KZKalliopi Zafeiropoulou
Kalliopi Zafeiropoulou
Georgios KalampouniasGeorgios Kalampounias
Georgios Kalampounias
SASpyridon Alexis
Spyridon Alexis
DADaniil Anastasopoulos
Daniil Anastasopoulos
Argiris SymeonidisArgiris Symeonidis
Argiris Symeonidis
Panagiotis KatsorisPanagiotis Katsoris
Panagiotis Katsoris
Proteasome inhibitors such as Bortezomib represent an established type of targeted treatment for several types of hematological malignancies, including multiple myeloma, Waldenstrom’s macroglobulinemia, and mantle cell lymphoma, based on the cancer cell’s susceptibility to impairment of the proteasome-ubiquitin system. However, a major problem limiting their efficacy is the emergence of resistance. Their application to solid tumors is currently being studied, while simultaneously, a wide spectrum of hematological cancers, such as Myelodysplastic Syndromes show minimal or no response to Bortezomib treatment. In this study, we utilize the prostate cancer cell line DU-145 to establish a model of Bortezomib resistance, studying the underlying mechanisms. Evaluating the resulting resistant cell line, we observed restoration of proteasome chymotrypsin-like activity, regardless of drug presence, an induction of pro-survival pathways, and the substitution of the Ubiquitin-Proteasome System role in proteostasis by induction of autophagy. Finally, an estimation of the oxidative condition of the cells indicated that the resistant clones reduce the generation of reactive oxygen species induced by Bortezomib to levels even lower than those induced in non-resistant cells. Our findings highlight the role of autophagy and oxidative stress regulation in Bortezomib resistance and elucidate key proteins of signaling pathways as potential pharmaceutical targets, which could increase the efficiency of proteasome-targeting therapies, thus expanding the group of molecular targets for neoplastic disorders.

12 November 2024 in Fermentation
Verified
Journal Article
Open access
PDF file
Georgios KalampouniasGeorgios Kalampounias
Georgios Kalampounias
PDPanagiotis Dritsas
Panagiotis Dritsas
Dimitris KarayannisDimitris Karayannis
Dimitris Karayannis
TATheodosia Androutsopoulou
Theodosia Androutsopoulou
CGChrysavgi Gardeli
Chrysavgi Gardeli
Panagiotis KatsorisPanagiotis Katsoris
Panagiotis Katsoris
Thamnidium elegans and Mortierella alpina are two oleaginous fungi that belong to Mucoromycota that synthesize polyunsaturated fatty acids, which are credited with multiple health benefits and possible anticancer properties. These fungi were cultivated on culture media, with glucose or glycerol as a carbon source. After extracting the lipids, we transformed them into fatty acid lithium salts (FALSs), which are water-soluble and absorbable mammalian cells, including DU-145 and PC-3 cancer cells. The two cell lines, both long-established prostate cancer models, were treated with FALSs and indicated increased susceptibility to the lipid derivatives. The viability and proliferation rates were significantly reduced, as well as their migratory capabilities, which were significantly impaired compared to olive oil-derived FALS, which was used as a control substance. We conclude that the FALS derivatives of microbial lipids from these organisms exhibit anticancer effects, by suppressing the proliferation and migration of human prostate cancer cell lines.

Verified
Journal Article
Open access
PDF file
Georgios KalampouniasGeorgios Kalampounias
Georgios Kalampounias
KZKalliopi Zafeiropoulou
Kalliopi Zafeiropoulou
TATheodosia Androutsopoulou
Theodosia Androutsopoulou
SASPYRIDON ALEXIS
SPYRIDON ALEXIS
Argiris SymeonidisArgiris Symeonidis
Argiris Symeonidis
Panagiotis KatsorisPanagiotis Katsoris
Panagiotis Katsoris
The rapid emergence of resistance limits the application of proteasome inhibitors against solid tumors, despite their effectiveness in the treatment of hematological malignancies. Resistant phenotypes are complex and multifaceted, and, thus, the mechanisms involved have not been adequately described. In this study, a Bortezomib-resistant prostate cancer cell line is created by using the PC-3 cell as a prostate carcinoma model of high metastatic potential. The main biochemical differences and adaptations exhibited by the resistant cells revolve around apoptosis evasion, autophagy induction (functioning as a ubiquitin-proteasome system substitute), expression of epithelial-to-mesenchymal transition markers, and increased aggressiveness. Broad-spectrum signaling pathway analyses also reveal an upregulation and activation of Nf-κB, STAT3, cJun, and Elk1 transcription factors in the resistant cells. Additionally, intracellular reactive oxygen species assays reveal a downregulation in resistant cells, which is theorized to be a consequence of metabolic changes, increased autophagic flux, and antioxidative enzyme action. These findings expand our understanding of proteasome inhibitor resistance and highlight key kinases and transcription factors as novel potential therapeutic targets. Effective inhibition of resistance-specific pathways could re-sensitize the cells to proteasome inhibitors, thus surpassing current therapeutic limitations.

Verified
Journal Article
Open access
PDF file
EPEva Plakoula
Eva Plakoula
Georgios KalampouniasGeorgios Kalampounias
Georgios Kalampounias
SASpyridon Alexis
Spyridon Alexis
EVEvgenia Verigou
Evgenia Verigou
AKAlexandra Kourakli
Alexandra Kourakli
Argiris SymeonidisArgiris Symeonidis
Argiris Symeonidis
Proteasome inhibitors (PIs) constitute the most common type of induction treatment for multiple myeloma. Interactions between the proteasome, autophagy, and reactive oxygen species (ROS) have been shown in the past, thus emphasizing the need for a better understanding of the underlying pathophysiology. For this study, bone marrow mononuclear cells from 110 myeloma patients were collected at different disease stages. PSMB5 and LC3I/II protein levels were determined using Western blot, proteasome proteolytic activity (PPA) with spectrofluorometry, and ROS with flow cytometry. PSMB5 accumulation was found to diminish after PI treatment (p-value = 0.014), and the same pattern was observed in PPA (p-value < 0.001). Conversely, LC3II protein levels were elevated at both remission and relapse compared to baseline levels (p-value = 0.041). Patients with a baseline PSMB5 accumulation lower than 1.06 units had longer disease-free survival compared to those with values above 1.06 units (12.0 ± 6.7 vs. 36 ± 12.1 months; p-value < 0.001). Median ROS levels in plasma cells were significantly higher at relapse compared to both baseline and remission levels (p-value < 0.001), implying poor prognosis. Overall, post-treatment PSMB5 reduction could indicate a shift from proteasomal to autophagic degradation as a main proteostatic mechanism, thus explaining resistance. The elevated oxidative stress in PI-treated patients could possibly serve as an additional compensatory mechanism.